We are live on ! Find out more
SWTX

SpringWorks Therapeutics

Delisted

SWTX was delisted on the 30th of June, 2025.

306 hedge funds and large institutions have $3.29B invested in SpringWorks Therapeutics in 2025 Q1 according to their latest regulatory filings, with 113 funds opening new positions, 85 increasing their positions, 86 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

414% more first-time investments, than exits

New positions opened: 113 | Existing positions closed: 22

141% more call options, than puts

Call options by funds: $287M | Put options by funds: $119M

42% more funds holding

Funds holding: 216306 (+90)

29% more funds holding in top 10

Funds holding in top 10: 79 (+2)

13% more capital invested

Capital invested by funds: $2.92B → $3.29B (+$368M)

1% less repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 86

9.3% less ownership

Funds ownership: 108.76%99.46% (-9.3%)

Holders
306
Holders Change
+90
Holders Change %
+41.67%
% of All Funds
4.1%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.12%
New
113
Increased
85
Reduced
86
Closed
22
Calls
$287M
Puts
$119M
Net Calls
+$168M
Net Calls Change
+$170M
Name Holding Trade Value Shares
Change
Change in
Stake
RC
151
Rangeley Capital
Connecticut
$1.47M +$1.54M +33,400 New
BHMP
152
Bardin Hill Management Partners
New York
$1.47M +$1.53M +33,300 New
PCM
153
Prelude Capital Management
New York
$1.38M +$679K +14,746 +90%
Los Angeles Capital Management
154
Los Angeles Capital Management
California
$1.35M -$1.43M -31,158 -50%
Wellington Management Group
155
Wellington Management Group
Massachusetts
$1.35M -$28.4K -618 -2%
BC
156
BIT Capital
Germany
$1.34M -$1.07M -23,282 -43%
EAM
157
Erste Asset Management
Austria
$1.29M +$690K +15,000 +122%
Janus Henderson Group
158
Janus Henderson Group
United Kingdom
$1.28M
SSA
159
Schonfeld Strategic Advisors
New York
$1.27M -$7.61M -165,226 -85%
PHS
160
PFM Health Sciences
California
$1.17M +$1.22M +26,437 New
SAM
161
Sectoral Asset Management
Quebec, Canada
$1.12M +$913K +19,825 +360%
KCM
162
Kennedy Capital Management
Missouri
$1.11M -$2.45M -53,130 -68%
Stifel Financial
163
Stifel Financial
Missouri
$1.11M +$63.9K +1,389 +6%
MS
164
Maven Securities
Jersey
$1.1M +$1.15M +25,010 New
CC
165
Centiva Capital
New York
$1.05M +$1.09M +23,750 New
Nomura Holdings
166
Nomura Holdings
Japan
$1.04M +$1.08M +23,500 New
Handelsbanken Fonder
167
Handelsbanken Fonder
Sweden
$1.03M
PA
168
Profund Advisors
Maryland
$1.03M -$40.5K -879 -4%
FLC
169
Fifth Lane Capital
Texas
$997K +$1.04M +22,584 New
SO
170
STRS Ohio
Ohio
$958K +$999K +21,700 New
Wolverine Trading
171
Wolverine Trading
Illinois
$908K +$881K +19,143 New
Ensign Peak Advisors
172
Ensign Peak Advisors
Utah
$849K +$9.21K +200 +1%
AIMCA
173
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$816K +$852K +18,500 New
HT
174
Headlands Technologies
Illinois
$807K +$623K +13,539 +285%
ProShare Advisors
175
ProShare Advisors
Maryland
$806K -$213K -4,621 -20%

SWTX Hedge Fund Activity: Q1 2025 in Review

306 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q1 2025, worth a combined $3.29B — up 13% from $2.92B a quarter earlier.

Buyers outnumbered sellers: 113 funds opened new SWTX positions and 22 closed out — a net gain of 91 holders — while 85 added to existing stakes and 86 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $58.7M. The largest seller was Deep Track Capital, exiting entirely with an estimated $125M sold.

  • 306 institutional investors held SpringWorks Therapeutics (SWTX) as of Q1 2025, up from 216 in Q4 2024.
  • Funds reported $3.29B of SpringWorks Therapeutics stock for Q1 2025, up 13% quarter-over-quarter.
  • 113 funds opened new SpringWorks Therapeutics positions in Q1 2025 and 22 closed out, a net change of +91 holders.
  • The largest SpringWorks Therapeutics buyer in Q1 2025 was D.E. Shaw & Co, an estimated $58.7M added.
  • The largest SpringWorks Therapeutics seller in Q1 2025 was Deep Track Capital, an estimated $125M sold.

Based on aggregated 13F filings for Q1 2025.